Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide for chronic sarcoidosis.

Robert P Baughman1, Marc A Judson, Alvin S Teirstein

  • 1Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA. Bob.Baughman@uc.edu

Chest
|July 13, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Have we resolved anything yet about sarcoidosis trials?

The European respiratory journal·2026
Same author

New proteomic biomarkers identified in plasma extracellular vesicles in sarcoidosis: a case-control matched study.

Frontiers in immunology·2026
Same author

Sarcoidosis: Disease mechanisms, diagnostic pathway and treatment.

Autoimmunity reviews·2026
Same author

Diagnostic accuracy of echocardiography in identifying heart failure related pleural effusions.

Respiratory medicine·2026
Same author

Incidence of New Comorbidities After Steroid Use in Patients With Sarcoidosis: An International Cross-Sectional Survey.

Chest·2025
Same author

Signal regulating proteins (SIRPs) participate in sarcoidosis granuloma formation by promoting immune cell aggregation.

Respiratory research·2025

Thalidomide effectively treated chronic cutaneous sarcoidosis, specifically lupus pernio. This therapy demonstrated good tolerability and offers a potential alternative to systemic corticosteroids for refractory cases.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Granulomatous diseases like tuberculosis and leprosy can be modified by thalidomide therapy.
  • Lupus pernio, a persistent skin manifestation of sarcoidosis, was utilized as a key indicator for assessing thalidomide's efficacy.

Purpose of the Study:

  • To evaluate the effectiveness of thalidomide in treating lupus pernio and other refractory sarcoidosis manifestations.
  • To assess the tolerability and safety profile of thalidomide in patients with chronic cutaneous sarcoidosis.

Main Methods:

  • An open-label, dose-escalation trial involving 15 patients with refractory sarcoidosis.
  • Patients received escalating doses of thalidomide, with skin lesions assessed via physician visual examination and blinded photographic evaluation.

Related Experiment Videos

  • Therapy duration and dosage varied, with assessments at 1, 2, and 3 months.

    • Main Results:

    • Fourteen patients completed 4 months of therapy, with all reporting subjective improvement in skin lesions.
    • Objective photographic scoring showed improvement in 10 out of 12 evaluable patients.
    • Common side effects included somnolence, numbness, and constipation; one patient discontinued due to dyspnea potentially related to heart failure.

    Conclusions:

    • Thalidomide is an effective treatment for chronic cutaneous sarcoidosis, including lupus pernio.
    • The drug is generally well-tolerated and presents a viable alternative to systemic corticosteroid therapy.
    • Further research may explore thalidomide's role in managing sarcoidosis complications.